nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—HTR2A—myenteric nerve plexus—stomach cancer	0.0188	0.158	CbGeAlD
Duloxetine—HTR2A—vagus nerve—stomach cancer	0.0126	0.106	CbGeAlD
Duloxetine—HTR2A—vein—stomach cancer	0.0121	0.102	CbGeAlD
Duloxetine—NPY1R—hematopoietic system—stomach cancer	0.01	0.0846	CbGeAlD
Duloxetine—NPY1R—pancreas—stomach cancer	0.00818	0.0689	CbGeAlD
Duloxetine—NPY1R—endocrine gland—stomach cancer	0.00577	0.0486	CbGeAlD
Duloxetine—NPY1R—liver—stomach cancer	0.00521	0.0438	CbGeAlD
Duloxetine—SLC6A3—hematopoietic system—stomach cancer	0.00423	0.0356	CbGeAlD
Duloxetine—NPY1R—lymph node—stomach cancer	0.00399	0.0336	CbGeAlD
Duloxetine—SLC6A4—hematopoietic system—stomach cancer	0.00387	0.0326	CbGeAlD
Duloxetine—HTR2A—blood vessel—stomach cancer	0.00385	0.0324	CbGeAlD
Duloxetine—SLC6A4—digestive system—stomach cancer	0.00269	0.0227	CbGeAlD
Duloxetine—CYP1A2—hematopoietic system—stomach cancer	0.00262	0.0221	CbGeAlD
Duloxetine—SLC6A4—endocrine gland—stomach cancer	0.00223	0.0187	CbGeAlD
Duloxetine—HTR2A—hematopoietic system—stomach cancer	0.00205	0.0173	CbGeAlD
Duloxetine—SLC6A2—endocrine gland—stomach cancer	0.00196	0.0165	CbGeAlD
Duloxetine—HTR2A—epithelium—stomach cancer	0.00187	0.0158	CbGeAlD
Duloxetine—CYP2D6—hematopoietic system—stomach cancer	0.00187	0.0157	CbGeAlD
Duloxetine—CYP1A2—digestive system—stomach cancer	0.00182	0.0153	CbGeAlD
Duloxetine—HTR2A—smooth muscle tissue—stomach cancer	0.00181	0.0152	CbGeAlD
Duloxetine—CYP1A2—endocrine gland—stomach cancer	0.00151	0.0127	CbGeAlD
Duloxetine—HTR2A—digestive system—stomach cancer	0.00143	0.012	CbGeAlD
Duloxetine—CYP1A2—liver—stomach cancer	0.00136	0.0114	CbGeAlD
Duloxetine—SLC6A2—lymph node—stomach cancer	0.00136	0.0114	CbGeAlD
Duloxetine—CYP2D6—digestive system—stomach cancer	0.0013	0.0109	CbGeAlD
Duloxetine—HTR2A—endocrine gland—stomach cancer	0.00118	0.00992	CbGeAlD
Duloxetine—CYP2D6—endocrine gland—stomach cancer	0.00107	0.00903	CbGeAlD
Duloxetine—HTR2A—liver—stomach cancer	0.00106	0.00894	CbGeAlD
Duloxetine—CYP2D6—liver—stomach cancer	0.000968	0.00814	CbGeAlD
Duloxetine—Propranolol—ADRB1—stomach cancer	0.000627	0.295	CrCbGaD
Duloxetine—Propranolol—HTR1A—stomach cancer	0.000561	0.264	CrCbGaD
Duloxetine—Propranolol—ADRB2—stomach cancer	0.000528	0.248	CrCbGaD
Duloxetine—Fluoxetine—ALB—stomach cancer	0.000413	0.194	CrCbGaD
Duloxetine—Hepatitis—Doxorubicin—stomach cancer	0.000333	0.000517	CcSEcCtD
Duloxetine—Haemorrhage—Doxorubicin—stomach cancer	0.000333	0.000517	CcSEcCtD
Duloxetine—Insomnia—Capecitabine—stomach cancer	0.000332	0.000516	CcSEcCtD
Duloxetine—Hypoaesthesia—Doxorubicin—stomach cancer	0.000332	0.000515	CcSEcCtD
Duloxetine—Rash—Fluorouracil—stomach cancer	0.000332	0.000514	CcSEcCtD
Duloxetine—Dermatitis—Fluorouracil—stomach cancer	0.000331	0.000514	CcSEcCtD
Duloxetine—Pharyngitis—Doxorubicin—stomach cancer	0.000331	0.000513	CcSEcCtD
Duloxetine—Paraesthesia—Capecitabine—stomach cancer	0.00033	0.000512	CcSEcCtD
Duloxetine—Decreased appetite—Docetaxel—stomach cancer	0.00033	0.000512	CcSEcCtD
Duloxetine—Headache—Fluorouracil—stomach cancer	0.000329	0.000511	CcSEcCtD
Duloxetine—Urinary tract disorder—Doxorubicin—stomach cancer	0.000329	0.000511	CcSEcCtD
Duloxetine—Oedema peripheral—Doxorubicin—stomach cancer	0.000328	0.00051	CcSEcCtD
Duloxetine—Dysgeusia—Methotrexate—stomach cancer	0.000328	0.000509	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Docetaxel—stomach cancer	0.000328	0.000508	CcSEcCtD
Duloxetine—Connective tissue disorder—Doxorubicin—stomach cancer	0.000328	0.000508	CcSEcCtD
Duloxetine—Fatigue—Docetaxel—stomach cancer	0.000327	0.000508	CcSEcCtD
Duloxetine—Angiopathy—Epirubicin—stomach cancer	0.000327	0.000507	CcSEcCtD
Duloxetine—Urethral disorder—Doxorubicin—stomach cancer	0.000327	0.000507	CcSEcCtD
Duloxetine—Nausea—Irinotecan—stomach cancer	0.000326	0.000506	CcSEcCtD
Duloxetine—Immune system disorder—Epirubicin—stomach cancer	0.000325	0.000505	CcSEcCtD
Duloxetine—Mediastinal disorder—Epirubicin—stomach cancer	0.000325	0.000504	CcSEcCtD
Duloxetine—Constipation—Docetaxel—stomach cancer	0.000325	0.000504	CcSEcCtD
Duloxetine—Pain—Docetaxel—stomach cancer	0.000325	0.000504	CcSEcCtD
Duloxetine—Back pain—Methotrexate—stomach cancer	0.000324	0.000503	CcSEcCtD
Duloxetine—Dyspepsia—Capecitabine—stomach cancer	0.000323	0.000502	CcSEcCtD
Duloxetine—Chills—Epirubicin—stomach cancer	0.000323	0.000502	CcSEcCtD
Duloxetine—Arrhythmia—Epirubicin—stomach cancer	0.000322	0.000499	CcSEcCtD
Duloxetine—Visual impairment—Doxorubicin—stomach cancer	0.000321	0.000498	CcSEcCtD
Duloxetine—Decreased appetite—Capecitabine—stomach cancer	0.000319	0.000496	CcSEcCtD
Duloxetine—Alopecia—Epirubicin—stomach cancer	0.000318	0.000494	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Capecitabine—stomach cancer	0.000317	0.000492	CcSEcCtD
Duloxetine—Fatigue—Capecitabine—stomach cancer	0.000317	0.000492	CcSEcCtD
Duloxetine—Vision blurred—Methotrexate—stomach cancer	0.000316	0.00049	CcSEcCtD
Duloxetine—Mental disorder—Epirubicin—stomach cancer	0.000316	0.00049	CcSEcCtD
Duloxetine—Erythema multiforme—Doxorubicin—stomach cancer	0.000315	0.000489	CcSEcCtD
Duloxetine—Pain—Capecitabine—stomach cancer	0.000314	0.000488	CcSEcCtD
Duloxetine—Constipation—Capecitabine—stomach cancer	0.000314	0.000488	CcSEcCtD
Duloxetine—Erythema—Epirubicin—stomach cancer	0.000314	0.000487	CcSEcCtD
Duloxetine—Malnutrition—Epirubicin—stomach cancer	0.000314	0.000487	CcSEcCtD
Duloxetine—Feeling abnormal—Docetaxel—stomach cancer	0.000313	0.000485	CcSEcCtD
Duloxetine—Nausea—Fluorouracil—stomach cancer	0.000312	0.000485	CcSEcCtD
Duloxetine—Eye disorder—Doxorubicin—stomach cancer	0.000312	0.000483	CcSEcCtD
Duloxetine—Ill-defined disorder—Methotrexate—stomach cancer	0.000311	0.000483	CcSEcCtD
Duloxetine—Tinnitus—Doxorubicin—stomach cancer	0.000311	0.000482	CcSEcCtD
Duloxetine—Gastrointestinal pain—Docetaxel—stomach cancer	0.00031	0.000482	CcSEcCtD
Duloxetine—Anaemia—Methotrexate—stomach cancer	0.00031	0.000481	CcSEcCtD
Duloxetine—Flushing—Doxorubicin—stomach cancer	0.000309	0.00048	CcSEcCtD
Duloxetine—Cardiac disorder—Doxorubicin—stomach cancer	0.000309	0.00048	CcSEcCtD
Duloxetine—Flatulence—Epirubicin—stomach cancer	0.000309	0.00048	CcSEcCtD
Duloxetine—Tension—Epirubicin—stomach cancer	0.000308	0.000478	CcSEcCtD
Duloxetine—Dysgeusia—Epirubicin—stomach cancer	0.000307	0.000477	CcSEcCtD
Duloxetine—Nervousness—Epirubicin—stomach cancer	0.000305	0.000473	CcSEcCtD
Duloxetine—Back pain—Epirubicin—stomach cancer	0.000303	0.000471	CcSEcCtD
Duloxetine—Feeling abnormal—Capecitabine—stomach cancer	0.000303	0.00047	CcSEcCtD
Duloxetine—Angiopathy—Doxorubicin—stomach cancer	0.000303	0.000469	CcSEcCtD
Duloxetine—Malaise—Methotrexate—stomach cancer	0.000302	0.000469	CcSEcCtD
Duloxetine—Muscle spasms—Epirubicin—stomach cancer	0.000302	0.000468	CcSEcCtD
Duloxetine—Immune system disorder—Doxorubicin—stomach cancer	0.000301	0.000467	CcSEcCtD
Duloxetine—Vertigo—Methotrexate—stomach cancer	0.000301	0.000467	CcSEcCtD
Duloxetine—Gastrointestinal pain—Capecitabine—stomach cancer	0.000301	0.000466	CcSEcCtD
Duloxetine—Mediastinal disorder—Doxorubicin—stomach cancer	0.000301	0.000466	CcSEcCtD
Duloxetine—Abdominal pain—Docetaxel—stomach cancer	0.0003	0.000465	CcSEcCtD
Duloxetine—Body temperature increased—Docetaxel—stomach cancer	0.0003	0.000465	CcSEcCtD
Duloxetine—Leukopenia—Methotrexate—stomach cancer	0.0003	0.000465	CcSEcCtD
Duloxetine—Chills—Doxorubicin—stomach cancer	0.000299	0.000464	CcSEcCtD
Duloxetine—Arrhythmia—Doxorubicin—stomach cancer	0.000298	0.000462	CcSEcCtD
Duloxetine—Vision blurred—Epirubicin—stomach cancer	0.000296	0.000459	CcSEcCtD
Duloxetine—Alopecia—Doxorubicin—stomach cancer	0.000295	0.000457	CcSEcCtD
Duloxetine—Cough—Methotrexate—stomach cancer	0.000293	0.000454	CcSEcCtD
Duloxetine—Mental disorder—Doxorubicin—stomach cancer	0.000292	0.000453	CcSEcCtD
Duloxetine—Urticaria—Capecitabine—stomach cancer	0.000292	0.000453	CcSEcCtD
Duloxetine—Ill-defined disorder—Epirubicin—stomach cancer	0.000291	0.000452	CcSEcCtD
Duloxetine—Body temperature increased—Capecitabine—stomach cancer	0.000291	0.000451	CcSEcCtD
Duloxetine—Abdominal pain—Capecitabine—stomach cancer	0.000291	0.000451	CcSEcCtD
Duloxetine—Convulsion—Methotrexate—stomach cancer	0.00029	0.000451	CcSEcCtD
Duloxetine—Malnutrition—Doxorubicin—stomach cancer	0.00029	0.00045	CcSEcCtD
Duloxetine—Erythema—Doxorubicin—stomach cancer	0.00029	0.00045	CcSEcCtD
Duloxetine—Anaemia—Epirubicin—stomach cancer	0.00029	0.00045	CcSEcCtD
Duloxetine—Agitation—Epirubicin—stomach cancer	0.000288	0.000447	CcSEcCtD
Duloxetine—Flatulence—Doxorubicin—stomach cancer	0.000286	0.000444	CcSEcCtD
Duloxetine—Chest pain—Methotrexate—stomach cancer	0.000285	0.000443	CcSEcCtD
Duloxetine—Myalgia—Methotrexate—stomach cancer	0.000285	0.000443	CcSEcCtD
Duloxetine—Arthralgia—Methotrexate—stomach cancer	0.000285	0.000443	CcSEcCtD
Duloxetine—Tension—Doxorubicin—stomach cancer	0.000285	0.000442	CcSEcCtD
Duloxetine—Dysgeusia—Doxorubicin—stomach cancer	0.000284	0.000441	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	0.000283	0.00044	CcSEcCtD
Duloxetine—Malaise—Epirubicin—stomach cancer	0.000283	0.000439	CcSEcCtD
Duloxetine—Discomfort—Methotrexate—stomach cancer	0.000282	0.000437	CcSEcCtD
Duloxetine—Nervousness—Doxorubicin—stomach cancer	0.000282	0.000437	CcSEcCtD
Duloxetine—Vertigo—Epirubicin—stomach cancer	0.000282	0.000437	CcSEcCtD
Duloxetine—Syncope—Epirubicin—stomach cancer	0.000281	0.000436	CcSEcCtD
Duloxetine—Leukopenia—Epirubicin—stomach cancer	0.000281	0.000436	CcSEcCtD
Duloxetine—Back pain—Doxorubicin—stomach cancer	0.000281	0.000436	CcSEcCtD
Duloxetine—Hypersensitivity—Docetaxel—stomach cancer	0.00028	0.000434	CcSEcCtD
Duloxetine—Muscle spasms—Doxorubicin—stomach cancer	0.000279	0.000433	CcSEcCtD
Duloxetine—Palpitations—Epirubicin—stomach cancer	0.000277	0.00043	CcSEcCtD
Duloxetine—Confusional state—Methotrexate—stomach cancer	0.000276	0.000428	CcSEcCtD
Duloxetine—Loss of consciousness—Epirubicin—stomach cancer	0.000276	0.000428	CcSEcCtD
Duloxetine—Cough—Epirubicin—stomach cancer	0.000274	0.000425	CcSEcCtD
Duloxetine—Anaphylactic shock—Methotrexate—stomach cancer	0.000274	0.000424	CcSEcCtD
Duloxetine—Vision blurred—Doxorubicin—stomach cancer	0.000274	0.000424	CcSEcCtD
Duloxetine—Asthenia—Docetaxel—stomach cancer	0.000272	0.000422	CcSEcCtD
Duloxetine—Convulsion—Epirubicin—stomach cancer	0.000272	0.000422	CcSEcCtD
Duloxetine—Infection—Methotrexate—stomach cancer	0.000272	0.000422	CcSEcCtD
Duloxetine—Hypertension—Epirubicin—stomach cancer	0.000271	0.00042	CcSEcCtD
Duloxetine—Hypersensitivity—Capecitabine—stomach cancer	0.000271	0.00042	CcSEcCtD
Duloxetine—Ill-defined disorder—Doxorubicin—stomach cancer	0.000269	0.000418	CcSEcCtD
Duloxetine—Pruritus—Docetaxel—stomach cancer	0.000269	0.000417	CcSEcCtD
Duloxetine—Nervous system disorder—Methotrexate—stomach cancer	0.000268	0.000416	CcSEcCtD
Duloxetine—Anaemia—Doxorubicin—stomach cancer	0.000268	0.000416	CcSEcCtD
Duloxetine—Thrombocytopenia—Methotrexate—stomach cancer	0.000268	0.000416	CcSEcCtD
Duloxetine—Chest pain—Epirubicin—stomach cancer	0.000267	0.000414	CcSEcCtD
Duloxetine—Myalgia—Epirubicin—stomach cancer	0.000267	0.000414	CcSEcCtD
Duloxetine—Arthralgia—Epirubicin—stomach cancer	0.000267	0.000414	CcSEcCtD
Duloxetine—Agitation—Doxorubicin—stomach cancer	0.000267	0.000414	CcSEcCtD
Duloxetine—Anxiety—Epirubicin—stomach cancer	0.000266	0.000413	CcSEcCtD
Duloxetine—Skin disorder—Methotrexate—stomach cancer	0.000266	0.000412	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	0.000265	0.000411	CcSEcCtD
Duloxetine—Hyperhidrosis—Methotrexate—stomach cancer	0.000264	0.00041	CcSEcCtD
Duloxetine—Discomfort—Epirubicin—stomach cancer	0.000264	0.000409	CcSEcCtD
Duloxetine—Asthenia—Capecitabine—stomach cancer	0.000264	0.000409	CcSEcCtD
Duloxetine—Malaise—Doxorubicin—stomach cancer	0.000262	0.000406	CcSEcCtD
Duloxetine—Dry mouth—Epirubicin—stomach cancer	0.000261	0.000405	CcSEcCtD
Duloxetine—Vertigo—Doxorubicin—stomach cancer	0.000261	0.000405	CcSEcCtD
Duloxetine—Anorexia—Methotrexate—stomach cancer	0.000261	0.000405	CcSEcCtD
Duloxetine—Syncope—Doxorubicin—stomach cancer	0.00026	0.000404	CcSEcCtD
Duloxetine—Pruritus—Capecitabine—stomach cancer	0.00026	0.000403	CcSEcCtD
Duloxetine—Leukopenia—Doxorubicin—stomach cancer	0.00026	0.000403	CcSEcCtD
Duloxetine—Diarrhoea—Docetaxel—stomach cancer	0.00026	0.000403	CcSEcCtD
Duloxetine—Confusional state—Epirubicin—stomach cancer	0.000258	0.0004	CcSEcCtD
Duloxetine—Palpitations—Doxorubicin—stomach cancer	0.000257	0.000398	CcSEcCtD
Duloxetine—Anaphylactic shock—Epirubicin—stomach cancer	0.000256	0.000397	CcSEcCtD
Duloxetine—Oedema—Epirubicin—stomach cancer	0.000256	0.000397	CcSEcCtD
Duloxetine—Loss of consciousness—Doxorubicin—stomach cancer	0.000255	0.000396	CcSEcCtD
Duloxetine—Infection—Epirubicin—stomach cancer	0.000254	0.000395	CcSEcCtD
Duloxetine—Cough—Doxorubicin—stomach cancer	0.000253	0.000393	CcSEcCtD
Duloxetine—Shock—Epirubicin—stomach cancer	0.000252	0.000391	CcSEcCtD
Duloxetine—Convulsion—Doxorubicin—stomach cancer	0.000251	0.00039	CcSEcCtD
Duloxetine—Diarrhoea—Capecitabine—stomach cancer	0.000251	0.00039	CcSEcCtD
Duloxetine—Nervous system disorder—Epirubicin—stomach cancer	0.000251	0.00039	CcSEcCtD
Duloxetine—Dizziness—Docetaxel—stomach cancer	0.000251	0.000389	CcSEcCtD
Duloxetine—Thrombocytopenia—Epirubicin—stomach cancer	0.000251	0.000389	CcSEcCtD
Duloxetine—Hypertension—Doxorubicin—stomach cancer	0.000251	0.000389	CcSEcCtD
Duloxetine—Tachycardia—Epirubicin—stomach cancer	0.00025	0.000388	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Methotrexate—stomach cancer	0.000249	0.000387	CcSEcCtD
Duloxetine—Skin disorder—Epirubicin—stomach cancer	0.000249	0.000386	CcSEcCtD
Duloxetine—Hyperhidrosis—Epirubicin—stomach cancer	0.000248	0.000384	CcSEcCtD
Duloxetine—Insomnia—Methotrexate—stomach cancer	0.000247	0.000384	CcSEcCtD
Duloxetine—Myalgia—Doxorubicin—stomach cancer	0.000247	0.000383	CcSEcCtD
Duloxetine—Arthralgia—Doxorubicin—stomach cancer	0.000247	0.000383	CcSEcCtD
Duloxetine—Chest pain—Doxorubicin—stomach cancer	0.000247	0.000383	CcSEcCtD
Duloxetine—Anxiety—Doxorubicin—stomach cancer	0.000246	0.000382	CcSEcCtD
Duloxetine—Paraesthesia—Methotrexate—stomach cancer	0.000246	0.000381	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	0.000245	0.000381	CcSEcCtD
Duloxetine—Discomfort—Doxorubicin—stomach cancer	0.000244	0.000379	CcSEcCtD
Duloxetine—Anorexia—Epirubicin—stomach cancer	0.000244	0.000379	CcSEcCtD
Duloxetine—Somnolence—Methotrexate—stomach cancer	0.000243	0.000377	CcSEcCtD
Duloxetine—Dizziness—Capecitabine—stomach cancer	0.000243	0.000377	CcSEcCtD
Duloxetine—Dry mouth—Doxorubicin—stomach cancer	0.000242	0.000375	CcSEcCtD
Duloxetine—Vomiting—Docetaxel—stomach cancer	0.000241	0.000374	CcSEcCtD
Duloxetine—Dyspepsia—Methotrexate—stomach cancer	0.000241	0.000374	CcSEcCtD
Duloxetine—Rash—Docetaxel—stomach cancer	0.000239	0.000371	CcSEcCtD
Duloxetine—Dermatitis—Docetaxel—stomach cancer	0.000239	0.000371	CcSEcCtD
Duloxetine—Confusional state—Doxorubicin—stomach cancer	0.000239	0.000371	CcSEcCtD
Duloxetine—Decreased appetite—Methotrexate—stomach cancer	0.000238	0.000369	CcSEcCtD
Duloxetine—Headache—Docetaxel—stomach cancer	0.000238	0.000369	CcSEcCtD
Duloxetine—Oedema—Doxorubicin—stomach cancer	0.000237	0.000368	CcSEcCtD
Duloxetine—Anaphylactic shock—Doxorubicin—stomach cancer	0.000237	0.000368	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Methotrexate—stomach cancer	0.000236	0.000366	CcSEcCtD
Duloxetine—Fatigue—Methotrexate—stomach cancer	0.000236	0.000366	CcSEcCtD
Duloxetine—Infection—Doxorubicin—stomach cancer	0.000235	0.000365	CcSEcCtD
Duloxetine—Pain—Methotrexate—stomach cancer	0.000234	0.000363	CcSEcCtD
Duloxetine—Vomiting—Capecitabine—stomach cancer	0.000234	0.000362	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Epirubicin—stomach cancer	0.000233	0.000362	CcSEcCtD
Duloxetine—Shock—Doxorubicin—stomach cancer	0.000233	0.000362	CcSEcCtD
Duloxetine—Nervous system disorder—Doxorubicin—stomach cancer	0.000232	0.00036	CcSEcCtD
Duloxetine—Thrombocytopenia—Doxorubicin—stomach cancer	0.000232	0.00036	CcSEcCtD
Duloxetine—Rash—Capecitabine—stomach cancer	0.000232	0.000359	CcSEcCtD
Duloxetine—Insomnia—Epirubicin—stomach cancer	0.000232	0.000359	CcSEcCtD
Duloxetine—Dermatitis—Capecitabine—stomach cancer	0.000232	0.000359	CcSEcCtD
Duloxetine—Tachycardia—Doxorubicin—stomach cancer	0.000231	0.000359	CcSEcCtD
Duloxetine—Headache—Capecitabine—stomach cancer	0.00023	0.000357	CcSEcCtD
Duloxetine—Skin disorder—Doxorubicin—stomach cancer	0.00023	0.000357	CcSEcCtD
Duloxetine—Paraesthesia—Epirubicin—stomach cancer	0.00023	0.000357	CcSEcCtD
Duloxetine—Hyperhidrosis—Doxorubicin—stomach cancer	0.000229	0.000355	CcSEcCtD
Duloxetine—Somnolence—Epirubicin—stomach cancer	0.000228	0.000353	CcSEcCtD
Duloxetine—Anorexia—Doxorubicin—stomach cancer	0.000226	0.00035	CcSEcCtD
Duloxetine—Nausea—Docetaxel—stomach cancer	0.000225	0.00035	CcSEcCtD
Duloxetine—Feeling abnormal—Methotrexate—stomach cancer	0.000225	0.00035	CcSEcCtD
Duloxetine—Dyspepsia—Epirubicin—stomach cancer	0.000225	0.00035	CcSEcCtD
Duloxetine—Gastrointestinal pain—Methotrexate—stomach cancer	0.000224	0.000347	CcSEcCtD
Duloxetine—Decreased appetite—Epirubicin—stomach cancer	0.000223	0.000345	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Epirubicin—stomach cancer	0.000221	0.000343	CcSEcCtD
Duloxetine—Fatigue—Epirubicin—stomach cancer	0.000221	0.000342	CcSEcCtD
Duloxetine—Pain—Epirubicin—stomach cancer	0.000219	0.00034	CcSEcCtD
Duloxetine—Constipation—Epirubicin—stomach cancer	0.000219	0.00034	CcSEcCtD
Duloxetine—Nausea—Capecitabine—stomach cancer	0.000218	0.000339	CcSEcCtD
Duloxetine—Urticaria—Methotrexate—stomach cancer	0.000217	0.000337	CcSEcCtD
Duloxetine—Body temperature increased—Methotrexate—stomach cancer	0.000216	0.000336	CcSEcCtD
Duloxetine—Abdominal pain—Methotrexate—stomach cancer	0.000216	0.000336	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Doxorubicin—stomach cancer	0.000216	0.000335	CcSEcCtD
Duloxetine—Insomnia—Doxorubicin—stomach cancer	0.000214	0.000332	CcSEcCtD
Duloxetine—Paraesthesia—Doxorubicin—stomach cancer	0.000213	0.00033	CcSEcCtD
Duloxetine—Feeling abnormal—Epirubicin—stomach cancer	0.000211	0.000327	CcSEcCtD
Duloxetine—Somnolence—Doxorubicin—stomach cancer	0.000211	0.000327	CcSEcCtD
Duloxetine—Gastrointestinal pain—Epirubicin—stomach cancer	0.000209	0.000325	CcSEcCtD
Duloxetine—Dyspepsia—Doxorubicin—stomach cancer	0.000209	0.000323	CcSEcCtD
Duloxetine—Decreased appetite—Doxorubicin—stomach cancer	0.000206	0.000319	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.000205	0.000317	CcSEcCtD
Duloxetine—Fatigue—Doxorubicin—stomach cancer	0.000204	0.000317	CcSEcCtD
Duloxetine—Urticaria—Epirubicin—stomach cancer	0.000203	0.000316	CcSEcCtD
Duloxetine—Pain—Doxorubicin—stomach cancer	0.000203	0.000314	CcSEcCtD
Duloxetine—Constipation—Doxorubicin—stomach cancer	0.000203	0.000314	CcSEcCtD
Duloxetine—Body temperature increased—Epirubicin—stomach cancer	0.000202	0.000314	CcSEcCtD
Duloxetine—Abdominal pain—Epirubicin—stomach cancer	0.000202	0.000314	CcSEcCtD
Duloxetine—Hypersensitivity—Methotrexate—stomach cancer	0.000202	0.000313	CcSEcCtD
Duloxetine—Asthenia—Methotrexate—stomach cancer	0.000196	0.000305	CcSEcCtD
Duloxetine—Feeling abnormal—Doxorubicin—stomach cancer	0.000195	0.000303	CcSEcCtD
Duloxetine—Gastrointestinal pain—Doxorubicin—stomach cancer	0.000194	0.000301	CcSEcCtD
Duloxetine—Pruritus—Methotrexate—stomach cancer	0.000194	0.0003	CcSEcCtD
Duloxetine—Hypersensitivity—Epirubicin—stomach cancer	0.000189	0.000293	CcSEcCtD
Duloxetine—Urticaria—Doxorubicin—stomach cancer	0.000188	0.000292	CcSEcCtD
Duloxetine—Body temperature increased—Doxorubicin—stomach cancer	0.000187	0.000291	CcSEcCtD
Duloxetine—Abdominal pain—Doxorubicin—stomach cancer	0.000187	0.000291	CcSEcCtD
Duloxetine—Diarrhoea—Methotrexate—stomach cancer	0.000187	0.00029	CcSEcCtD
Duloxetine—Asthenia—Epirubicin—stomach cancer	0.000184	0.000285	CcSEcCtD
Duloxetine—Pruritus—Epirubicin—stomach cancer	0.000181	0.000281	CcSEcCtD
Duloxetine—Dizziness—Methotrexate—stomach cancer	0.000181	0.000281	CcSEcCtD
Duloxetine—Diarrhoea—Epirubicin—stomach cancer	0.000175	0.000272	CcSEcCtD
Duloxetine—Hypersensitivity—Doxorubicin—stomach cancer	0.000175	0.000271	CcSEcCtD
Duloxetine—Vomiting—Methotrexate—stomach cancer	0.000174	0.00027	CcSEcCtD
Duloxetine—Rash—Methotrexate—stomach cancer	0.000172	0.000268	CcSEcCtD
Duloxetine—Dermatitis—Methotrexate—stomach cancer	0.000172	0.000267	CcSEcCtD
Duloxetine—Headache—Methotrexate—stomach cancer	0.000171	0.000266	CcSEcCtD
Duloxetine—Asthenia—Doxorubicin—stomach cancer	0.00017	0.000264	CcSEcCtD
Duloxetine—Dizziness—Epirubicin—stomach cancer	0.000169	0.000263	CcSEcCtD
Duloxetine—Pruritus—Doxorubicin—stomach cancer	0.000168	0.00026	CcSEcCtD
Duloxetine—Vomiting—Epirubicin—stomach cancer	0.000163	0.000253	CcSEcCtD
Duloxetine—Nausea—Methotrexate—stomach cancer	0.000163	0.000252	CcSEcCtD
Duloxetine—Diarrhoea—Doxorubicin—stomach cancer	0.000162	0.000251	CcSEcCtD
Duloxetine—Rash—Epirubicin—stomach cancer	0.000161	0.00025	CcSEcCtD
Duloxetine—Dermatitis—Epirubicin—stomach cancer	0.000161	0.00025	CcSEcCtD
Duloxetine—Headache—Epirubicin—stomach cancer	0.00016	0.000249	CcSEcCtD
Duloxetine—Dizziness—Doxorubicin—stomach cancer	0.000157	0.000243	CcSEcCtD
Duloxetine—Nausea—Epirubicin—stomach cancer	0.000152	0.000236	CcSEcCtD
Duloxetine—Vomiting—Doxorubicin—stomach cancer	0.000151	0.000234	CcSEcCtD
Duloxetine—Rash—Doxorubicin—stomach cancer	0.000149	0.000232	CcSEcCtD
Duloxetine—Dermatitis—Doxorubicin—stomach cancer	0.000149	0.000232	CcSEcCtD
Duloxetine—Headache—Doxorubicin—stomach cancer	0.000148	0.00023	CcSEcCtD
Duloxetine—Nausea—Doxorubicin—stomach cancer	0.000141	0.000218	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—STAT3—stomach cancer	5.33e-05	0.000227	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6R—stomach cancer	5.22e-05	0.000223	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—UMPS—stomach cancer	5.2e-05	0.000222	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—RHOA—stomach cancer	5.19e-05	0.000222	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RBP4—stomach cancer	5.16e-05	0.00022	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCL8—stomach cancer	5.16e-05	0.00022	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—stomach cancer	5.14e-05	0.000219	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HSPB1—stomach cancer	5.11e-05	0.000218	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AGTR2—stomach cancer	5.11e-05	0.000218	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MAPK3—stomach cancer	5.1e-05	0.000217	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLIN2—stomach cancer	5.08e-05	0.000217	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ADRB2—stomach cancer	5.07e-05	0.000216	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BMP2—stomach cancer	5.06e-05	0.000216	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—F2R—stomach cancer	5.06e-05	0.000216	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKR1C3—stomach cancer	4.97e-05	0.000212	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PPP2R1A—stomach cancer	4.96e-05	0.000212	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MYC—stomach cancer	4.96e-05	0.000211	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CA2—stomach cancer	4.94e-05	0.000211	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HTR1A—stomach cancer	4.92e-05	0.00021	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MAPK1—stomach cancer	4.85e-05	0.000207	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EGFR—stomach cancer	4.85e-05	0.000207	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PDHA1—stomach cancer	4.83e-05	0.000206	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ECHS1—stomach cancer	4.83e-05	0.000206	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NT5E—stomach cancer	4.81e-05	0.000205	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PGAM1—stomach cancer	4.81e-05	0.000205	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PRKCB—stomach cancer	4.77e-05	0.000203	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ANXA1—stomach cancer	4.75e-05	0.000203	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—RHOA—stomach cancer	4.72e-05	0.000201	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SMAD4—stomach cancer	4.61e-05	0.000197	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADRB1—stomach cancer	4.6e-05	0.000196	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLCE1—stomach cancer	4.59e-05	0.000196	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALDH7A1—stomach cancer	4.59e-05	0.000196	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—KRAS—stomach cancer	4.58e-05	0.000195	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCL8—stomach cancer	4.56e-05	0.000195	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—FADS1—stomach cancer	4.54e-05	0.000194	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TYMP—stomach cancer	4.54e-05	0.000194	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AGTR2—stomach cancer	4.44e-05	0.000189	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HSPB1—stomach cancer	4.44e-05	0.000189	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—UMPS—stomach cancer	4.4e-05	0.000188	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RPS6—stomach cancer	4.4e-05	0.000188	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—F2R—stomach cancer	4.39e-05	0.000187	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BMP2—stomach cancer	4.39e-05	0.000187	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FYN—stomach cancer	4.38e-05	0.000187	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PRKCB—stomach cancer	4.33e-05	0.000185	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKR1C3—stomach cancer	4.32e-05	0.000184	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6ST—stomach cancer	4.31e-05	0.000184	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HTR1A—stomach cancer	4.27e-05	0.000182	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SREBF2—stomach cancer	4.25e-05	0.000181	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PIK3CA—stomach cancer	4.21e-05	0.000179	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—RORA—stomach cancer	4.2e-05	0.000179	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCL8—stomach cancer	4.14e-05	0.000177	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PRKCB—stomach cancer	4.14e-05	0.000177	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ANXA1—stomach cancer	4.13e-05	0.000176	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FGFR2—stomach cancer	4.11e-05	0.000175	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PDHA1—stomach cancer	4.09e-05	0.000175	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ECHS1—stomach cancer	4.09e-05	0.000175	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—stomach cancer	4.07e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HBEGF—stomach cancer	4.04e-05	0.000172	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADRB1—stomach cancer	4e-05	0.000171	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALDOB—stomach cancer	3.94e-05	0.000168	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HRAS—stomach cancer	3.89e-05	0.000166	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—FADS1—stomach cancer	3.85e-05	0.000164	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TYMP—stomach cancer	3.85e-05	0.000164	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6R—stomach cancer	3.85e-05	0.000164	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—RHOA—stomach cancer	3.83e-05	0.000163	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RPS6—stomach cancer	3.82e-05	0.000163	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IRS2—stomach cancer	3.76e-05	0.00016	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PRKCB—stomach cancer	3.76e-05	0.00016	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6ST—stomach cancer	3.74e-05	0.00016	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADRB2—stomach cancer	3.73e-05	0.000159	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—stomach cancer	3.73e-05	0.000159	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALOX5—stomach cancer	3.66e-05	0.000156	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PPP2R1A—stomach cancer	3.66e-05	0.000156	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CAV1—stomach cancer	3.65e-05	0.000156	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOA1—stomach cancer	3.64e-05	0.000155	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SREBF2—stomach cancer	3.6e-05	0.000154	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—DPYD—stomach cancer	3.6e-05	0.000154	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—RORA—stomach cancer	3.56e-05	0.000152	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HBEGF—stomach cancer	3.51e-05	0.00015	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—RHOA—stomach cancer	3.47e-05	0.000148	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PRKCB—stomach cancer	3.47e-05	0.000148	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6ST—stomach cancer	3.46e-05	0.000147	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SMAD4—stomach cancer	3.39e-05	0.000145	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL8—stomach cancer	3.36e-05	0.000143	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6R—stomach cancer	3.34e-05	0.000142	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALDOB—stomach cancer	3.34e-05	0.000142	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APC—stomach cancer	3.32e-05	0.000142	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—RHOA—stomach cancer	3.32e-05	0.000142	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADRB2—stomach cancer	3.24e-05	0.000138	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FYN—stomach cancer	3.22e-05	0.000137	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTT1—stomach cancer	3.18e-05	0.000136	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MAPK3—stomach cancer	3.18e-05	0.000136	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PPP2R1A—stomach cancer	3.17e-05	0.000135	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP2A6—stomach cancer	3.15e-05	0.000134	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—stomach cancer	3.15e-05	0.000134	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—stomach cancer	3.14e-05	0.000134	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALOX5—stomach cancer	3.1e-05	0.000132	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6R—stomach cancer	3.08e-05	0.000132	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKR1C3—stomach cancer	3.06e-05	0.000131	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—DPYD—stomach cancer	3.05e-05	0.00013	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL8—stomach cancer	3.05e-05	0.00013	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MAPK1—stomach cancer	3.03e-05	0.000129	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EGFR—stomach cancer	3.03e-05	0.000129	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGFR2—stomach cancer	3.03e-05	0.000129	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—RHOA—stomach cancer	3.02e-05	0.000129	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ENO1—stomach cancer	2.98e-05	0.000127	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SMAD4—stomach cancer	2.95e-05	0.000126	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL8—stomach cancer	2.92e-05	0.000124	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CA—stomach cancer	2.89e-05	0.000123	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SERPINE1—stomach cancer	2.89e-05	0.000123	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—KRAS—stomach cancer	2.86e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FYN—stomach cancer	2.8e-05	0.000119	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RHOA—stomach cancer	2.79e-05	0.000119	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IRS2—stomach cancer	2.77e-05	0.000118	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—stomach cancer	2.77e-05	0.000118	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOS3—stomach cancer	2.76e-05	0.000118	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTT1—stomach cancer	2.7e-05	0.000115	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CAV1—stomach cancer	2.69e-05	0.000115	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOA1—stomach cancer	2.68e-05	0.000114	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2A6—stomach cancer	2.67e-05	0.000114	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL8—stomach cancer	2.65e-05	0.000113	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CD44—stomach cancer	2.65e-05	0.000113	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CA—stomach cancer	2.63e-05	0.000112	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGFR2—stomach cancer	2.63e-05	0.000112	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKR1C3—stomach cancer	2.59e-05	0.000111	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ERBB2—stomach cancer	2.58e-05	0.00011	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PRKCB—stomach cancer	2.56e-05	0.000109	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6ST—stomach cancer	2.55e-05	0.000109	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ENO1—stomach cancer	2.53e-05	0.000108	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—stomach cancer	2.49e-05	0.000106	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APC—stomach cancer	2.45e-05	0.000104	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL8—stomach cancer	2.45e-05	0.000104	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HRAS—stomach cancer	2.43e-05	0.000104	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IRS2—stomach cancer	2.41e-05	0.000103	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1B—stomach cancer	2.39e-05	0.000102	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK3—stomach cancer	2.34e-05	9.99e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CAV1—stomach cancer	2.33e-05	9.95e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOA1—stomach cancer	2.33e-05	9.93e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—stomach cancer	2.33e-05	9.92e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—stomach cancer	2.28e-05	9.72e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—JUN—stomach cancer	2.27e-05	9.7e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6R—stomach cancer	2.27e-05	9.69e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPP2R1A—stomach cancer	2.25e-05	9.6e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CD44—stomach cancer	2.24e-05	9.56e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK1—stomach cancer	2.23e-05	9.51e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—stomach cancer	2.23e-05	9.51e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRKCB—stomach cancer	2.22e-05	9.47e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—stomach cancer	2.21e-05	9.44e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6ST—stomach cancer	2.21e-05	9.43e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTP1—stomach cancer	2.21e-05	9.42e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1A—stomach cancer	2.2e-05	9.4e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMOX1—stomach cancer	2.18e-05	9.29e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	2.18e-05	9.28e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK8—stomach cancer	2.15e-05	9.18e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CA—stomach cancer	2.13e-05	9.09e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SERPINE1—stomach cancer	2.13e-05	9.07e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APC—stomach cancer	2.12e-05	9.06e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KRAS—stomach cancer	2.11e-05	8.98e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TYMS—stomach cancer	2.05e-05	8.75e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RHOA—stomach cancer	2.05e-05	8.75e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK3—stomach cancer	2.03e-05	8.68e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOS3—stomach cancer	2.03e-05	8.66e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTM1—stomach cancer	2.03e-05	8.65e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—stomach cancer	1.99e-05	8.47e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6R—stomach cancer	1.97e-05	8.41e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—stomach cancer	1.97e-05	8.39e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK1—stomach cancer	1.94e-05	8.26e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—stomach cancer	1.94e-05	8.26e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CA—stomach cancer	1.93e-05	8.25e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ERCC2—stomach cancer	1.91e-05	8.14e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPP2R1A—stomach cancer	1.91e-05	8.13e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB2—stomach cancer	1.9e-05	8.1e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK3—stomach cancer	1.88e-05	8.02e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTP1—stomach cancer	1.87e-05	7.98e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CA—stomach cancer	1.85e-05	7.89e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SERPINE1—stomach cancer	1.85e-05	7.88e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMOX1—stomach cancer	1.84e-05	7.87e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KRAS—stomach cancer	1.83e-05	7.8e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—stomach cancer	1.83e-05	7.8e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL8—stomach cancer	1.8e-05	7.68e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTHFR—stomach cancer	1.79e-05	7.65e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HRAS—stomach cancer	1.79e-05	7.63e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK1—stomach cancer	1.79e-05	7.63e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—stomach cancer	1.79e-05	7.63e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RHOA—stomach cancer	1.78e-05	7.6e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOS3—stomach cancer	1.76e-05	7.52e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1B—stomach cancer	1.76e-05	7.5e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TYMS—stomach cancer	1.74e-05	7.42e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTM1—stomach cancer	1.72e-05	7.33e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—stomach cancer	1.71e-05	7.31e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KRAS—stomach cancer	1.69e-05	7.2e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CA—stomach cancer	1.68e-05	7.17e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—stomach cancer	1.68e-05	7.16e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JUN—stomach cancer	1.67e-05	7.14e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CAV1—stomach cancer	1.65e-05	7.05e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOA1—stomach cancer	1.65e-05	7.04e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB2—stomach cancer	1.65e-05	7.04e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—stomach cancer	1.63e-05	6.95e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1A—stomach cancer	1.62e-05	6.93e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ERCC2—stomach cancer	1.62e-05	6.89e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK8—stomach cancer	1.58e-05	6.76e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL8—stomach cancer	1.56e-05	6.67e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HRAS—stomach cancer	1.55e-05	6.63e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CA—stomach cancer	1.55e-05	6.62e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1B—stomach cancer	1.53e-05	6.52e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTHFR—stomach cancer	1.52e-05	6.48e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—stomach cancer	1.5e-05	6.4e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—stomach cancer	1.49e-05	6.35e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—stomach cancer	1.46e-05	6.24e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—stomach cancer	1.46e-05	6.22e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JUN—stomach cancer	1.45e-05	6.2e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARG—stomach cancer	1.45e-05	6.2e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—stomach cancer	1.45e-05	6.18e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HRAS—stomach cancer	1.44e-05	6.12e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—stomach cancer	1.41e-05	6.04e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1A—stomach cancer	1.41e-05	6.01e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CAV1—stomach cancer	1.4e-05	5.98e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOA1—stomach cancer	1.4e-05	5.96e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK3—stomach cancer	1.38e-05	5.9e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK8—stomach cancer	1.38e-05	5.87e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—stomach cancer	1.37e-05	5.86e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—stomach cancer	1.35e-05	5.74e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	1.34e-05	5.71e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK1—stomach cancer	1.32e-05	5.62e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—stomach cancer	1.32e-05	5.62e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—stomach cancer	1.31e-05	5.58e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—stomach cancer	1.27e-05	5.42e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—stomach cancer	1.26e-05	5.37e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NOS3—stomach cancer	1.25e-05	5.33e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KRAS—stomach cancer	1.24e-05	5.31e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARG—stomach cancer	1.23e-05	5.25e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK3—stomach cancer	1.2e-05	5.13e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—stomach cancer	1.17e-05	4.99e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK1—stomach cancer	1.14e-05	4.88e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—stomach cancer	1.14e-05	4.88e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—stomach cancer	1.14e-05	4.88e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CA—stomach cancer	1.14e-05	4.87e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—stomach cancer	1.11e-05	4.72e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—stomach cancer	1.11e-05	4.72e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KRAS—stomach cancer	1.08e-05	4.61e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NOS3—stomach cancer	1.06e-05	4.52e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HRAS—stomach cancer	1.06e-05	4.51e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—stomach cancer	1.01e-05	4.32e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CA—stomach cancer	9.92e-06	4.23e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—stomach cancer	9.69e-06	4.13e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—stomach cancer	9.6e-06	4.09e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRAS—stomach cancer	9.18e-06	3.92e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—stomach cancer	8.79e-06	3.75e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CA—stomach cancer	7.04e-06	3e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CA—stomach cancer	5.96e-06	2.54e-05	CbGpPWpGaD
